37 citations
,
May 2003 in “Journal of Consumer Marketing”
The debate on direct-to-consumer pharmaceutical ads continues, with consumers finding them educational and doctors concerned about their impact on patient relationships and medication understanding.
The conversation discusses using 1% cetirizine, an antihistamine, as a potential treatment for androgenetic alopecia (hair loss). One user plans to try cetirizine instead of finasteride, while others are curious or skeptical about its effectiveness, discussing the role of inflammation in hair loss.
Trump's health report omits finasteride, sparking speculation about whether he stopped using it or switched treatments. Some believe he might not prioritize hair maintenance anymore.
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
A user experienced an allergic reaction, including swollen lymph nodes, to Minoxidil 5% with an aqueous base. Switching to a non-alcohol-based Minoxidil (Prolox 5%) resolved the allergies.
A user shared their successful hair regrowth using a combination of minoxidil, caffeine, biotin, and RU58841, along with weekly dermarolling. However, others advised against the user's plan to switch to rosemary oil and microneedling only, emphasizing the importance of continuing the current treatment to maintain the results.